EritreaTuberculosis profile
Population  2014 5.1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.71 (0.46–1) 14 (9–20)
Mortality (HIV+TB only) 0.1 (0.058–0.15) 2 (1.1–3)
Prevalence  (includes HIV+TB) 6.3 (3.2–10) 123 (63–203)
Incidence  (includes HIV+TB) 4 (2.9–5.2) 78 (57–103)
Incidence (HIV+TB only) 0.25 (0.18–0.34) 4.9 (3.5–6.6)
         
Case detection, all forms (%) 60 (46–82)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
25 (5–46) 26 (7–46)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 771   86
Pulmonary, clinically diagnosed 714   34
Extrapulmonary 774   12
       
Total new and relapse 2 391    
Previously treated, excluding relapses 34    
Total cases notified 2 425    
Among 2 391 new and relapse cases:
306 (13%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     22
Patients started on MDR-TB treatment ***     24
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 311 (95)
HIV-positive TB patients 140 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 104 (74)
HIV-positive TB patients on antiretroviral therapy (ART) 115 (82)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (89) 2 862
Previously treated cases, excluding relapse, registered in 2013 (77) 107
HIV-positive TB cases, all types, registered in 2013 (79) 147
RR-/MDR-TB cases started on second-line treatment in 2012 (100) 1
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 1.0
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 5
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-13 Data: www.who.int/tb/data